Swiss pharmaceutical company Novartis AG said Thursday it received a contract worth up to $220 million from the Department of Health and Human Services to develop a cell culture-derived flu vaccine for seasonal vaccines and rapid response to a potential flu pandemic. Financial News USA (http://www.financialnewsusa.com/release.php?rlsid=5052)